Results 11 to 20 of about 1,612 (203)

Droxidopa for Management of Chronic Hypotension in Hemodialysis [PDF]

Kidney International Reports
Anuradha Jayanti, Mohamed Elewa
doaj   +4 more sources

Impact of COVID‑19 infection on subsequent prescriptions of autonomic dysfunction pharmacotherapy: a nationwide propensity‑score‑matched Cohort study in Japan [PDF]

Annals of Medicine
Background Autonomic dysfunction, including orthostatic hypotension and postural tachycardia syndrome, has emerged as a COVID-19 complication.
Daisuke Miyamori, Masanori Ito
doaj   +2 more sources

L-DOPA and Droxidopa: From Force Field Development to Molecular Docking into Human β₂-Adrenergic Receptor [PDF]

Life, 2022
The increasing interest in the molecular mechanism of the binding of different agonists and antagonists to β2-adrenergic receptor (β2AR) inactive and active states has led us to investigate protein–ligand interactions using molecular docking calculations.
Andrea Catte, Akash Deep Biswas, Giordano Mancini, Vincenzo Barone   +3 more
doaj   +2 more sources

Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa

Journal of Market Access & Health Policy, 2022
Background Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life.
Clément François, Nicola Germain, Renata Majewska, Vanessa Taieb, L. Arthur Hewitt, Steven Kymes   +5 more
doaj   +2 more sources

Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases [PDF]

Frontiers in Neurology, 2023
BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki, Yayoi Kawata, Ayako Hayashi, Masaki Arai, Shinji Fujimoto   +4 more
doaj   +3 more sources

Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST. [PDF]

PLoS ONE
BackgroundNon-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice ...
Masahiro Nomoto, Yoshio Tsuboi, Kenichi Kashihara, Shih-Wei Chiu, Tetsuya Maeda, Hidemoto Saiki, Hirohisa Watanabe, Yasushi Shimo, Nobutaka Hattori, Takuhiro Yamaguchi, J-FIRST Investigators   +10 more
doaj   +2 more sources

Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy? [PDF]

Brain Commun
A feature shared by many different neurodegenerative diseases is early pathology and degeneration of the pontine locus coeruleus. The human locus coeruleus contains about 50 000 neurons and is the primary source of the neurotransmitter noradrenaline.
Durcan R, O'Callaghan C, Rowe JB.
europepmc   +6 more sources

Fix or Adapt? Rethinking the Management of Complex Autonomic Dysfunction in an Older Adult Following Orthopedic Surgery. [PDF]

Geriatr Gerontol Int
Geriatrics &Gerontology International, Volume 25, Issue 12, Page 1962-1964, December 2025.
De Louche CD, Palliyage S.
europepmc   +2 more sources

Droxidopa for neurogenic orthostatic hypotension [PDF]

Neurology, 2014
To determine whether droxidopa, an oral norepinephrine precursor, improves symptomatic neurogenic orthostatic hypotension (nOH).Patients with symptomatic nOH due to Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization (100-600 mg 3 times daily), followed,
Horacio Kaufmann, Roy Freeman, Italo Biaggioni, Phillip A. Low, Simon C.J. Pedder, L. Arthur Hewitt, Joe Mauney, Michael Feirtag, Christopher J. Mathias   +8 more
openalex   +4 more sources

Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde [PDF]

Clinical Chemistry, 2010
AbstractBackground: l-Threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa) is a norepinephrine (NE) prodrug under development to treat orthostatic hypotension. 3,4-Dihydroxyphenylacetaldehyde (DOPAL), an endogenous catecholaldehyde produced by enzymatic oxidative deamination of dopamine, is toxic to catecholaminergic neurons. Based on the observation of
Courtney Holmes, Noel F. Whittaker, Jorge Heredia‐Moya, David S. Goldstein   +3 more
  +5 more sources